Seribantumab (MM-121) was granted by the FDA as fast track designation for NRG1-positive, locally advanced, or metastatic NSCLC after failure of immunotherapy based on the SHERLOC trial (NCT02387216). Here, NRG1 is linked to non-small cell lung carcinoma.